Keyword: Novartis

While Seqirus works to boost manufacturing for its cell-based flu vaccine in the U.S., the shot is nearing an approval in Europe.

Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.

The first ad campaign for Novartis and Amgen migraine med Aimovig celebrates life’s ups and downs, and that migraine sufferers should be there for all of it.

Lilly did not make a plausible case that its drug is more cost-effective than other CDK 4/6 inhibitors, England's drug-price watchdog said.

Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.

In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval.

Merck is joining the chief digital officer parade, hiring Jim Scholefield from Nike to head up IT and digital strategy—not to mention cybersecurity.

Teva lost a patent appeal for multiple sclerosis blockbuster Copaxone, a drug that has seen a considerable sales decline due to generics.

AbbVie has inked a fourth patent deal on its megablockbuster Humira that forces Novartis to the back of the line for a U.S. launch.

Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.